Clinical trial · no report yet · Phase 3
PREOPANC-3
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
- NCT04927780 ↗
- Active not recruiting
- Erasmus Medical Center
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 22 | |
| Podcasts | 8 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma
- Interventions
- Leucovorin Calcium; Fluorouracil; Irinotecan Hydrochloride; Oxaliplatin; Resection
- Arms
- Arm 1: Perioperative mFOLFIRINOX · Experimental
- Arm 2: Adjuvant mFOLFIRINOX · Active comparator
- Enrollment
- 378 (estimated)
- Primary outcomes
- Overall survival
- Sponsor
- Erasmus Medical Center with Dutch Pancreatic Cancer Group, Dutch Cancer Society
- Start
- Sep 7, 2021
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04927780 · updated May 15, 2026
Publications
linked from the registry- van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, Busch OR, van Driel LMJW, van Eijck CHJ, Feshtali S, Ghorbani P, de Groot DJA, de Groot JWB, Haberkorn BCM, de Hingh IH, van der Holt B, Karsten TM, van der Kolk MB, Labori KJ, Liem MSL, Loosveld OJL, Molenaar IQ, Polee MB, van Santvoort HC, de Vos-Geelen J, Wumkes ML, van Tienhoven G, Homs MYV, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023 Aug 7;23(1):728. doi: 10.1186/s12885-023-11141-5. PubMed 37550634